半導體板塊領漲A股 晶豐明源、聞泰科技等多股漲停
格隆匯1月20日丨A股三大指數紛紛上漲,半導體板塊領漲。其中,晶豐明源(688368.SH)漲停,樂鑫科技(688018.SH)漲超14%,富滿電子、聞泰科技和耐威科技等漲停,晶方科技和納斯達逼近漲停,揚傑科技、中穎電子、中環股份、兆易創新、北京君正和韋爾股份等均出現明顯漲幅。聞泰科技17日晚發佈業績預告稱,預計2019年年度實現歸屬於上市公司股東的淨利潤為12.5億元-15億元,同比增加1949%-2358%。業內分析人士對格隆匯表示,隨着部分半導體公司發佈盈喜預告,透露出2019年半導體行業的爆炸式增長,整個半導體板塊的走勢將被帶動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.